Patent ID: 8106078

Claim:
A method for regulating angiogenesis in a human, comprising administering to a human an effective amount of a compound having the formula: wherein R is a substituted or unsubstituted thiazolyl unit having the formula: R 2 and R 3 are each independently chosen from: i) hydrogen; ii) substituted or unsubstituted C 1 -C 6 linear, C 3 -C 6 branched, or C 3 -C 6 cyclic alkyl; iii) substituted or unsubstituted phenyl; iv) substituted or unsubstituted heteroaryl; or R 2 and R 3 can be taken together to form a saturated or unsaturated ring having from 5 to 7 atoms; said substitutions are independently chosen from one or more C 1 -C 6 linear, C 3 -C 6 branched, or C 1 -C 6 cyclic alkyl, —N(R 11 ) 2 , —OR 11 , halogen, hydroxyl, or cyano units; each R 11 is independently hydrogen, C 11 linear or C 3 -C 4 branched alkyl; R 4 is a unit chosen from: i) hydrogen; ii) substituted or unsubstituted C 1 -C 6 linear, C 3 -C 6 branched, or C 3 -C 6 cyclic alkyl; iii) substituted or unsubstituted phenyl; or iv) substituted or unsubstituted heteroaryl; said substitutions are independently chosen from one or more C 1 -C 6 linear, C 3 -C 6 branched, or C 1 -C 6 cyclic alkyl, —N(R 11 ) 2 , —OR 11 , halogen, hydroxyl, or cyano units; each R 11 is independently hydrogen, C 1 -C 4 linear or C 3 -C 4 branched alkyl; Z is a unit having the formula: R 1 is chosen from: i) hydrogen; ii) substituted or unsubstituted C 1 -C 6 linear, C 3 -C 6 branched, or C 3 -C 6 cyclic alkyl; iii) substituted or unsubstituted aryl; iv) substituted or unsubstituted heterocyclic rings; or v) substituted or unsubstituted heteroaryl rings; said substitutions are independently chosen from one or more halogen, C 1 -C 6 linear, C 3 -C 6 branched, or C 3 -C 6 cyclic alkyl, —OR 11 , —CN, —N(R 11 ) 2 , —CO 2 R 11 , —C(O)N(R 11 ) 2 , —NR 11 C(O)R 11 , —NO 2 , —SO 2 R 11 , phenyl, benzyl; when R 1 is substituted by phenyl or benzyl, said phenyl or benzyl can be substituted by halogen, C 1 -C 3 alkyl, C 1 -C 3 alkoxy, —CO 2 R 11 and —NHCOR 16 ; each R 11 is independently hydrogen; substituted or unsubstituted C 1 -C 4 linear, branched, cyclic alkyl, alkenyl, or alkynyl; substituted or unsubstituted phenyl or benzyl; or two R 11 units can be taken together to form a ring comprising from 3-7 atoms; each R 16 is independently hydrogen, methyl, or ethyl; L is a linking unit chosen from: i) —C(O)NH[C(R 5a R 5b )] w —; ii) —C(O)[C(R 6a R 6b )]—; iii) —C(O)[C(R 7a R 7b )] y C(O)—; iv) —SO 2 [C(R 8a R 8b )] z —; R 5a , R 5b , R 6a , R 6b , R 7a , R 7b , R 8a , and R 8b are each independently: i) hydrogen; ii) substituted or unsubstituted C 1 -C 4 linear or C 3 -C 4 branched alkyl; iii) substituted or unsubstituted aryl; iv) substituted or unsubstituted heterocyclic rings; or v) substituted or unsubstituted heteroaryl rings; the index n is 0 or 1; the indices w and z are each independently from 0 to 4 and the indices x and y are each independently from 1 to 4; or a pharmaceutically acceptable salt thereof.